Lilly Launches Phase 2 FORAY Trial of FGFR3 Inhibitor Vepugratinib in Early Bladder Cancer
核心洞察
Eli Lilly has opened a Phase 2 trial called FORAY testing the oral FGFR3 (搜索) inhibitor vepugratinib (搜索) in adults with early bladder and upper tract urothelial cancers.
The study targets low grade, intermediate risk tumors carrying FGFR3 (搜索) alterations, a setting where targeted treatment options are currently limited.
FORAY is an open-label, randomized parallel-group interventional trial that is listed as not yet recruiting, with each patient followed for up to five years.
Eli Lilly and Company has launched a Phase 2 study of vepugratinib (搜索) in adults with certain early bladder and upper tract urothelial cancers, according to a newly posted ClinicalTrials registry entry. The trial, named FORAY, will assess how well the oral agent controls low grade, intermediate risk tumors that carry FGFR3 (搜索) changes, and will track safety over time in a setting where new targeted options are limited.
Mechanism and Rationale
Vepugratinib (搜索), also known as LY3866288, is an oral drug designed to block FGFR3 (搜索), a signaling pathway linked to tumor growth in some bladder and upper tract cancers. The stated goal of treatment is to delay or prevent disease return.
The study population consists of adults with non-muscle invasive bladder and upper tract urothelial cancer (搜索) whose tumors harbor FGFR3 (搜索) alterations. The focus on low grade, intermediate risk disease places the program in an early-stage setting rather than advanced or metastatic disease.
Trial Design
FORAY is an interventional trial that randomly assigns participants to different treatment groups running in parallel. It is open label, meaning both physicians and patients know they are receiving vepugratinib (搜索). The trial's main purpose is treatment rather than prevention or diagnosis.
The registry lists the study as not yet recruiting. First submission and the latest update both carry the date September 15, 2026, indicating a fresh entry to the ClinicalTrials registry. Primary and final completion dates have not yet been posted. Each patient may be followed for up to five years, which points to long-term outcome and safety tracking as part of the study's design.
Positioning in Lilly's Oncology Pipeline
The FORAY listing reflects Lilly's continued push into targeted oncology beyond its current portfolio. Positive results in FGFR3 (搜索)-altered bladder and upper tract cancers could support a future niche launch in a precision medicine setting, and would place the program alongside other FGFR-directed efforts in development. Any clinical readout and subsequent regulatory path remain several years away given the trial's not-yet-recruiting status and the absence of posted completion dates.
Further details on the FORAY study of vepugratinib (搜索) in non-muscle invasive bladder and upper tract urothelial cancer (搜索) are available on the ClinicalTrials portal.